EUVIMEDEUVIMED entdecken
Crossref

Patterns of antiseizure medication utilization in the Human Epilepsy Project

Jonah Fox iD, Sarah Barnard iD, Shruti H Agashe iD, Manisha G Holmes, Barry Gidal iD, Pavel Klein iD, Bassel W Abou-Khalil, Jacqueline French iD, Human Epilepsy Project Investigators

Epilepsia · 2023

DOI: 10.1111/epi.17802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Jonah Fox und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Epilepsy, Epilepsies, Partial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to ascertain the natural history and patterns of antiseizure medication (ASM) use in newly diagnosed focal epilepsy patients who were initially started on monotherapy.

Methods

The data were derived from the Human Epilepsy Project. Differences between the durations of the most commonly first prescribed ASM monotherapies were assessed using a Cox proportional hazards model. Subjects were classified into three groups: monotherapy, sequential monotherapy, and polytherapy.

Results

A total of 443 patients were included in the analysis, with a median age of 32 years (interquartile range [IQR] = 20–44) and median follow‐up time of 3.2 years (IQR = 2.4–4.2); 161 (36.3%) patients remained on monotherapy with their initially prescribed ASM at the time of their last follow‐up. The mean (SEM) and median (IQR) duration that patients stayed on monotherapy with their initial ASM was 2.1 (2.0–2.2) and 1.9 (.3–3.5) years, respectively. The most commonly prescribed initial ASM was levetiracetam (254, 57.3%), followed by lamotrigine (77, 17.4%), oxcarbazepine (38, 8.6%), and carbamazepine (24, 5.4%). Among those who did not remain on the initial monotherapy, 167 (59.2%) transitioned to another ASM as monotherapy (sequential monotherapy) and 115 (40.8%) ended up on polytherapy. Patients remained significantly longer on lamotrigine (mean = 2.8 years, median = 3.1 years) compared to levetiracetam (mean = 2.0 years, median = 1.5 years) as a first prescribed medication (hazard ratio = 1.5, 95% confidence interval = 1.0–2.2). As the study progressed, the proportion of patients on lamotrigine, carbamazepine, and oxcarbazepine as well as other sodium channel agents increased from a little more than one third (154, 34.8%) of patients to more than two thirds (303, 68.4%) of patients. Significance Slightly more than one third of focal epilepsy patients remain on monotherapy with their first prescribed ASM. Approximately three in five patients transition to monotherapy with another ASM, whereas approximately two in five end up on polytherapy. Patients remain on lamotrigine for a longer duration compared to levetiracetam when it is prescribed as the initial monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyEpilepsies, PartialHumansYoung AdultAdultLamotrigineOxcarbazepineLevetiracetamAnticonvulsantsCarbamazepineBenzodiazepines

Stichwörter der Autor:innen

natural historypolytherapysequential monotherapy

Substanzen

LamotrigineOxcarbazepineLevetiracetamAnticonvulsantsCarbamazepineBenzodiazepines

Autor:innen und Institutionen

  • Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Neuroscience, Alfred Center, Monash University, Melbourne, Victoria, Australia.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Westchester Medical Center, Valhalla, New York, USA.
  • School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, USA.

ORCID-Profile: Jonah Fox, Sarah Barnard, Shruti H Agashe, Barry Gidal, Pavel Klein, Jacqueline French

Zitieren

APA

Fox, J., Barnard, S., Agashe, S. H., Holmes, M. G., Gidal, B., Klein, P., Abou-Khalil, B. W., French, J., & Human Epilepsy Project Investigators (2023). Patterns of antiseizure medication utilization in the Human Epilepsy Project. Epilepsia. https://doi.org/10.1111/epi.17802

Vancouver

Fox J, Barnard S, Agashe SH, Holmes MG, Gidal B, Klein P, et al. Patterns of antiseizure medication utilization in the Human Epilepsy Project. Epilepsia. 2023. doi:10.1111/epi.17802

BibTeX
@article{Fox2023,
  author = {Fox, Jonah and Barnard, Sarah and Agashe, Shruti H and Holmes, Manisha G and Gidal, Barry and Klein, Pavel and Abou-Khalil, Bassel W and French, Jacqueline and Human Epilepsy Project Investigators, Human Epilepsy Project Investigators},
  title = {Patterns of antiseizure medication utilization in the Human Epilepsy Project},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17802}
}
Kostenlos starten →